Oncology Business Management | Specialty

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

AACR Rally Protests Cuts to NIH Budget

April 8th 2013

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Medicare Reimbursement Cuts Caused by Sequestration Begin to Take Effect

April 4th 2013

As a result of sequestration-related federal budget cuts, Medicare reimbursement has been reduced by 2% across the board, with the reduction affecting a number of services offered to cancer patients.

The Economic Value of Ipilimumab as a Second-Line Treatment in Patients With Advanced Melanoma

April 3rd 2013

Analysis of the cost-effectiveness of ipilimumab compared with best supportive care in previously treated patients with advanced (unresectable or metastatic) melanoma.

Conclusion: Optimal Side Effect Management in CRC

April 2nd 2013

Case Study: Treating Metastatic Colorectal Cancer

April 2nd 2013

Second-Line Therapies for Patients With mCRC

April 2nd 2013

Determining Optimal Treatments in mCRC

April 2nd 2013

Treatment Sequencing in Metastatic Colorectal Cancer

April 2nd 2013

Treating Unresectable Metastatic Colorectal Cancer

April 2nd 2013

Treating Resectable Metastatic Colorectal Cancer

April 2nd 2013

Exploring the Neoadjuvant Treatment of Rectal Cancer

April 2nd 2013

Understanding the Role of Aspirin in Colorectal Cancer

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part II

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part I

April 2nd 2013

Practice Benchmark Report Offers Hope for Survival of Independent Oncology Practices

March 29th 2013

The narrowing difference between operating cost and total medical revenue has eased, buying some time for practices to adjust their business models and perhaps survive.

Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML

March 28th 2013

Although it is now standard practice to utilize the second-generation TKIs dasatinib or nilotinib in patients whose CML has recurred while taking imatinib treatment, published support for the economic value of this approach is lacking.

Dr. Gomella on Sequencing Prostate Cancer Therapies

March 25th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

Trials Should Test Combinations, Sequences of Novel Treatments for Prostate Cancer

March 18th 2013

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.